Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study

Fecha de publicación: 01/06/2020

Autores de IIS La Fe

María Isabel Del Olmo García

Autor
David Hervás Marín

Autor
Jana Caudet Esteban

Autor
Antonio Ballesteros Martín Portugués

Autor
Alba Cervero Rubio

Autor
Miguel Ángel Arnau Vives

Autor
Ana Isabel Catalá Gregori

Autor
Juan Francisco Merino Torres

Autor

Participantes ajenos a IIS La Fe

Martinez, MP

Grupos

Grupo de Investigación Clínica y Traslacional en Cardiología

Investigador Principal

Esther Roselló Lletí
Unidad Mixta de Investigación en Endocrinología, Nutrición y Dietética clínica

Leader

Juan Francisco Merino Torres

Abstract

Objective To explore the glucagon-like peptide-1 analogue liraglutide in the hospital setting in patients with type 2 diabetes mellitus (T2DM) and acute coronary syndrome and to evaluate the safety and efficacy and its impact on hospitalization and short-term glycemic variability (GV). Methods A 12-week, open-label, prospective, randomized pilot clinical study with parallel groups that compared liraglutide (group 1) with glargine (group 2) and its impact on glycemic control and GV. Results Thirteen patients were included. During hospitalization, mean glucose was 164.75 mg/dL (standard deviation [SD] 19.94) in group 1 and 166.69 mg/dL (38.22) in group 2. GV determined by CV and SD was 20.98 (7.68) vs. 25.48 (7.19) and 34.37 (13.05) vs. 43.56 (19.53) in groups 1 and 2, respectively. Group 1 prandial insulin requirements during hospitalization were lower compared with group 2. Follow-up A1c in group 1 was 6.9% (-1.51%) and 6.5% in group 2 (-1.27). GV after discharge and hypoglycemia were lower in group 1 compared with group 2. Conclusions Liraglutide seems to reduce GV in the acute phase of acute coronary syndrome, and patients achieved optimal control with a low incidence of hypoglycemia. These results support the need to explore liraglutide in a larger multicenter trial.

Datos de la publicación

ISSN/ISSNe:: 0300-0605, 1473-2300
Tipo:: Article
Páginas:: -
DOI:: 10.1177/0300060520926063
Factor de Impacto:: 0,421 SCImago ℠
Cuartil:: Q3 SCImago ℠

Documentos

No hay documentos

Métricas

Filiaciones

del Olmo-Garcia, MI:: Hosp Univ La Fe Valencia, Valenciana, Spain

Instituto de Investigación. IIS La Fe, Unidad Mixta Invest Endocrinol Nutr & Dietet, Valenciana, Spain
Marin, DH:: Instituto de Investigación. Inst Invest Sanitaria IIS La Fe Valencia, Unidad Bioestadist, Valenciana, Spain
Esteban, JC:: Hosp Univ La Fe Valencia, Valenciana, Spain

Instituto de Investigación. IIS La Fe, Unidad Mixta Invest Endocrinol Nutr & Dietet, Valenciana, Spain
Martin-Portugues, AB:: Hosp Univ La Fe Valencia, Valenciana, Spain
Rubio, AC:: Hosp Univ La Fe Valencia, Valenciana, Spain
Vives, MAA:: Hosp Univ La Fe Valencia, Valenciana, Spain
Gregori, AC:: Instituto de Investigación. IIS La Fe, Unidad Mixta Invest Endocrinol Nutr & Dietet, Valenciana, Spain
Martinez, MP:: Hosp Univ La Fe Valencia, Valenciana, Spain
Merino-Torres, JF:: Hosp Univ La Fe Valencia, Valenciana, Spain

Instituto de Investigación. IIS La Fe, Unidad Mixta Invest Endocrinol Nutr & Dietet, Valenciana, Spain

Univ Valencia, Dept Med, Valenciana, Spain